-
Mashup Score: 1
Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers in the study’s 2 cohorts.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Panelists Share How CLEAR and KEYNOTE-426 Data Presented at ASCO 2023 Impact Treatment Decisions | GU Oncology Now - 2 year(s) ago
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
From our roundtable discussion on the CLEAR and KEYNOTE-426 data, @PBarataMD shares his thoughts on what the results mean for IO/TKI treatment. See what our other expert panelists said about this new data: https://t.co/V6QykpULdu https://t.co/Y8P0ExD220
-
-
Mashup Score: 1
Dr. Albiges details what KEYMAKER-U03B hopes to accomplish, outcomes for patients in arm B5, and next lines of research for belzutifan.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
.@AlbigesL shares with us her take on a key finding in the KEYNOTE-B61 study, of which results were published yesterday in @TheLancetOncol. The treatment paradigm for untreated advanced non-clear-cell RCC is changing...https://t.co/X3jwtPdZJu https://t.co/4l0lZtGKTm
-
-
Mashup Score: 1
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as a late-breaking abstract at the ASCO 2023 Annual Meeting.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
The PEACE-1 study results on ADT and #docetaxel with abiraterone acetate plus prednisone are discussed by @AlbertoBossial and @WallisCJD in our latest interview. Watch now: https://t.co/D1Kafb7G0E https://t.co/AP6dHxzW8l
-
-
Mashup Score: 4Panel Comments on Most Impactful Studies and Data in Bladder Cancer | GU Oncology Now - 2 year(s) ago
The panel discusses studies and areas of interest related to treatment options for advanced bladder cancer.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
.@DanielPetrylak of @SmilowCancer expands on the challenge of designing clinical trials for #bladdercancer today in our roundtable discussion. Do you agree with his concerns? https://t.co/UKnLadII9q https://t.co/PLxpRIyIt0
-
-
Mashup Score: 0
Drs. Matin and Ambinder discuss the data that supports performing lymph node dissection at time of surgery for UTUC, as well as risk factors for patients.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
.@SimplyUroMD and @SurenaMatinMD of @MDAndersonNews hit on supporting data for lymph node dissection during surgery for UTUC. How challenging is determining which lymph nodes to target? https://t.co/1b95YWbZvJ https://t.co/LFTn4GcTAA
-
-
Mashup Score: 0The Uromigos Episode 251: Final Part of VEGF/TKI vs IPI/NIVO Discussion | GU Oncology Now - 2 year(s) ago
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are covered along with previously discussed endpoints.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
In the latest @Uromigos episode, @Merregan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. Listen now: https://t.co/ZmpIFZdyi2 https://t.co/Wp31NfQZoB
-
-
Mashup Score: 0
Several experts discuss the evolution of nephrectomy as a treatment approach, how it is used today, which patients are best suited for it, and more.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
Several kidney cancer experts provide their insights on the evolution of #nephrectomy as a treatment approach, how it is used today, which patients are best suited for it, and how it figures to exist as a treatment option in the coming years. Read more: https://t.co/Q1dIBHAphZ https://t.co/L85fWoyPRm
-
-
Mashup Score: 0Panelists Discuss Treatment Approach for Patients With Cisplatin-Eligible Bladder Cancer | GU Oncology Now - 2 year(s) ago
The panel discusses the approach to treating patients with cisplatin-eligible bladder cancer.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Fox Chase's Dr. @MattZibelman joins a roundtable discussion on the best approaches to treating patients with cisplatin-eligible bladder cancer, led by Dr. Vadim Koshkin . Watch now: https://t.co/zZ1FO3L03p
-
-
Mashup Score: 0
Drs. Matin and Ambinder discuss the data that supports performing lymph node dissection at time of surgery for UTUC, as well as risk factors for patients.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
In our latest interview series, @SurenaMatinMD and @SimplyUroMD discuss the data that supports performing lymph node dissection at time of surgery for #UTUC, as well as the risk factors for individual patients. Watch now: https://t.co/VJtPOPGC7Z https://t.co/a1TBQu7OHV
-
The @Uromigos are joined by @neerajaiims in their latest episode to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers in the study’s 2 cohorts. Listen now: https://t.co/4EFo1lGVpW https://t.co/OlzGbjmxHy